FR21C1060I2 - Ligands des recepteurs de la melanocortine - Google Patents

Ligands des recepteurs de la melanocortine

Info

Publication number
FR21C1060I2
FR21C1060I2 FR21C1060C FR21C1060C FR21C1060I2 FR 21C1060 I2 FR21C1060 I2 FR 21C1060I2 FR 21C1060 C FR21C1060 C FR 21C1060C FR 21C1060 C FR21C1060 C FR 21C1060C FR 21C1060 I2 FR21C1060 I2 FR 21C1060I2
Authority
FR
France
Prior art keywords
receptor ligands
melanocortin receptor
melanocortin
ligands
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR21C1060C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Original Assignee
Ipsen Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma SAS filed Critical Ipsen Pharma SAS
Publication of FR21C1060I1 publication Critical patent/FR21C1060I1/fr
Application granted granted Critical
Publication of FR21C1060I2 publication Critical patent/FR21C1060I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
FR21C1060C 2005-07-08 2021-12-14 Ligands des recepteurs de la melanocortine Active FR21C1060I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69777905P 2005-07-08 2005-07-08
US74885005P 2005-12-09 2005-12-09
EP06786665A EP1915167A4 (fr) 2005-07-08 2006-07-10 Ligands des recepteurs de la melanocortine

Publications (2)

Publication Number Publication Date
FR21C1060I1 FR21C1060I1 (fr) 2022-01-21
FR21C1060I2 true FR21C1060I2 (fr) 2022-12-02

Family

ID=37637790

Family Applications (1)

Application Number Title Priority Date Filing Date
FR21C1060C Active FR21C1060I2 (fr) 2005-07-08 2021-12-14 Ligands des recepteurs de la melanocortine

Country Status (21)

Country Link
US (8) US8039435B2 (fr)
EP (6) EP2236151B1 (fr)
JP (4) JP4734411B2 (fr)
KR (2) KR101232201B1 (fr)
CN (4) CN105837661A (fr)
AU (2) AU2006269261B2 (fr)
CA (4) CA3044795A1 (fr)
DK (4) DK2236151T3 (fr)
ES (4) ES2877349T3 (fr)
FR (1) FR21C1060I2 (fr)
HK (2) HK1149190A1 (fr)
HU (4) HUE037147T2 (fr)
IL (3) IL188545A (fr)
NL (1) NL301150I2 (fr)
NZ (2) NZ565217A (fr)
PL (4) PL2286825T3 (fr)
PT (4) PT2236151E (fr)
RU (2) RU2439079C2 (fr)
SG (1) SG163585A1 (fr)
SI (1) SI3354273T1 (fr)
WO (1) WO2007008704A2 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007020152A1 (de) * 2007-04-26 2008-10-30 Charité - Universitätsmedizin Berlin Mittel zur antiinfektiven Behandlung eines Patienten
RU2450017C2 (ru) 2007-05-25 2012-05-10 Ипсен Фарма С.А.С. Лиганды меланокортиновых рецепторов, модифицированные гидантоином
AR066175A1 (es) * 2007-06-15 2009-08-05 Sod Conseils Rech Applic Ligandos del receptor de melanocortina de peptidos ciclicos
AU2008325194B2 (en) 2007-11-05 2012-04-19 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use melanocortins to treat insulin sensitivity
KR101666631B1 (ko) * 2008-05-27 2016-10-17 젠자임 코포레이션 알파-멜라노사이트 자극 호르몬의 펩티드 유사체
CA2727317C (fr) 2008-06-09 2015-02-17 Palatin Technologies, Inc. Peptides specifiques du recepteur de melanocortine pour le traitement d'un dysfonctionnement sexuel
EP2440572B1 (fr) 2009-06-08 2017-04-05 Palatin Technologies, Inc. Peptides spécifiques des récepteurs aux mélanocortines à pont lactame
AU2010259008C1 (en) 2009-06-08 2016-04-21 Palatin Technologies, Inc. Melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
IN2012DN01493A (fr) * 2009-08-05 2015-06-05 Ipsen Pharma Sas
WO2011026015A2 (fr) * 2009-08-31 2011-03-03 Gruber Kenneth A Ligands de mélanocortine stabilisés
JP5486690B2 (ja) * 2009-11-16 2014-05-07 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ メラノコルチン受容体リガンドの医薬組成物
CN102686601A (zh) * 2009-11-16 2012-09-19 益普生制药股份有限公司 合成Ac-Arg-环(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2的方法
WO2011063367A1 (fr) 2009-11-23 2011-05-26 Palatin Technologies, Inc. Peptides linéaires spécifiques du récepteur de la mélanocortine-1
KR101921761B1 (ko) 2009-11-23 2018-11-23 팔라틴 테크놀로지스 인코포레이티드 멜라노코르틴-1 수용체 특이적 고리형 펩티드
BR112013027222B1 (pt) * 2011-06-14 2022-07-12 Ipsen Pharma S.A.S. Composição de liberação sustentada que contém peptídeos como ingrediente ativo
DK3539551T3 (da) 2011-12-29 2021-11-01 Rhythm Pharmaceuticals Inc Fremgangsmåde til behandling af melanocortin-4 receptor-associerede forstyrrelser i heterozygotiske bærere
EP2705835A1 (fr) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
JP6429782B2 (ja) * 2012-10-19 2018-11-28 ティーエックスピー・ファルマ・ゲーエムベーハー アルファ−およびガンマ−ｍｓｈアナログ
US10232018B2 (en) 2013-03-14 2019-03-19 Mallinckrodt Ard Ip Limited ACTH for treatment of acute respiratory distress syndrome
RU2020120797A (ru) * 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
KR102378943B1 (ko) * 2013-03-15 2022-03-25 리듬 파마슈티컬즈, 인코포레이티드 약학적 조성물
ES2854353T3 (es) 2014-04-22 2021-09-21 Txp Pharma Gmbh Análogos péptidicos con sonda(s) aminoacídicas ramificadas
MA43040A (fr) * 2015-09-30 2018-08-08 Univ Berlin Charite Méthode de traitement de troubles associés à la voie du récepteur de la mélanocortine 4
US11542302B2 (en) 2015-10-15 2023-01-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulators of melanocortin receptors for the treatment of depression and anxiety
WO2017066754A1 (fr) * 2015-10-15 2017-04-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions et méthodes de traitement de la dépression et de l'anxiété
WO2018074999A1 (fr) * 2016-10-17 2018-04-26 The Arizona Board Of Regents On Behalf Of The University Of Arizona Nouveaux modulateurs des récepteurs de mélanocortine pour le traitement de la dépression et de l'anxiété
EP3596107A1 (fr) * 2017-03-15 2020-01-22 Novo Nordisk A/S Composés bicycliques aptes à se lier au récepteur de mélanocortine 4
EP3773897A1 (fr) 2018-04-06 2021-02-17 Rhythm Pharmaceuticals, Inc. Compositions pour le traitement d'une rénopathie
WO2019219714A1 (fr) * 2018-05-15 2019-11-21 Novo Nordisk A/S Composés capables de se lier au récepteur de la mélanocortine 4
CA3100868A1 (fr) * 2018-05-23 2019-11-28 Provincial Health Services Authority Analogues d'hormone stimulant des melanocytes alpha specifiques du recepteur de la melanocortine de type 1 radiomarques pour l'imagerie ou la therapie
US11396535B2 (en) 2019-03-01 2022-07-26 Provincial Health Services Authority Cyclic peptide analogs of melanocortin and amanitin and methods of making such
JP2023542985A (ja) * 2020-09-24 2023-10-12 リズム ファーマシューティカルズ， インコーポレイテッド メラノコルチン－４受容体経路関連障害の治療方法
WO2022251650A1 (fr) * 2021-05-27 2022-12-01 The Regents Of The University Of Michigan Peptides agonistes du mc3r
WO2024083843A1 (fr) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Séquences d'acides aminés dirigées contre le récepteur de la mélanocortine 4 et polypeptides les comprenant pour le traitement de maladies et de troubles liés à mc4r

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US613874A (en) 1898-11-08 George e
US1613874A (en) 1922-03-29 1927-01-11 Miner Inc W H Friction draft gear
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
SE9700620D0 (sv) 1997-02-21 1997-02-21 Wapharm Ab Cykliska peptider med selektivitet för MSH-receptor subtyper
US6350430B1 (en) 1997-10-27 2002-02-26 Lion Bioscience Science Ag Melanocortin receptor ligands and methods of using same
WO1999055679A1 (fr) 1998-04-28 1999-11-04 Trega Biosciences, Inc. Composes a base d'isoquinoline tenant lieu de ligands de recepteurs de melanocortine et procedes d'utilisation
AU758179B2 (en) * 1998-07-27 2003-03-20 Iowa State University Research Foundation Inc. Melanocortin-4 receptor gene and use as a genetic marker for fat content, weight gain, and/or feed consumption of animals
AU775289B2 (en) 1998-08-21 2004-07-29 Children's Medical Center Corporation Use of melanin for inhibition of angiogenesis and macular degeneration
US6716810B1 (en) 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
TR200102765T2 (tr) 1999-03-29 2002-05-21 The Procter & Gamble Company Melanokortin reseptör ligandları
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
EP1241933B1 (fr) 1999-11-12 2008-10-01 Merck & Co., Inc. Cellules presentant une carence du recepteur de la melanocortine 3, souris transgeniques et methodes de selection de composes regulant le poids corporel
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
BR0111567A (pt) * 2000-06-28 2003-05-06 Pfizer Prod Inc Ligandos do receptor de melanocortina
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
AU2001292658A1 (en) 2000-09-13 2002-03-26 Eleanor Roosevelt Institute Method for treatment of insulin resistance in obesity and diabetes
US20030113263A1 (en) 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
HUP0303484A2 (hu) 2001-03-02 2004-01-28 Bristol-Myers Squibb Company Melanokortin receptor modulátoraiként hasznos vegyületek és a vegyületeket tartalmazó gyógyszerkészítmények
US6770645B2 (en) * 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
IL159797A0 (en) * 2001-07-11 2004-06-20 Palatin Technologies Inc Linear and cyclic melanocortin receptor-specific peptides
US7034004B2 (en) 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US20040128136A1 (en) * 2002-09-20 2004-07-01 Irani Pourang Polad Internet voice browser
WO2005000338A1 (fr) * 2003-06-19 2005-01-06 Eli Lilly And Company Utilisation de peptides agonistes du recepteur de la melanocortine-3 (mc3r)
CA2530024A1 (fr) * 2003-06-19 2005-01-06 Eli Lilly And Company Agonistes du recepteur 4 de la melanocortine (mc4) et utilisations
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
AU2004267044B8 (en) 2003-08-20 2009-12-17 Emisphere Technologies, Inc. Compounds, methods and formulations for the oral delivery of a glucagon like peptide (GLP)-1 compound or an melanocortin 4 receptor (MC4) agonist peptide
ATE350369T1 (de) * 2003-08-20 2007-01-15 Lilly Co Eli Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4- rezeptor (mc4) als agonist wirkenden peptids
US20050192286A1 (en) * 2003-10-22 2005-09-01 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
DE10355559A1 (de) 2003-11-21 2005-06-23 Orthogen Ag Transskin
US20070155660A1 (en) 2003-12-10 2007-07-05 Marsh Donald J Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists
WO2005102377A1 (fr) * 2004-03-29 2005-11-03 Eli Lilly And Company Utilisations de peptides agonistes du recepteur de la melanocortine 4 (mc4r) administres par perfusion continue
AU2005291862B2 (en) 2004-10-08 2010-07-08 Clinuvel Pharmaceuticals Limited Compositions and methods for inducing melanogenesis in a subject
WO2006073771A2 (fr) 2005-01-05 2006-07-13 Eli Lilly And Company Peptides d'agonistes mc4r ou mc3r lies au polyethyleneglycol
WO2006073772A1 (fr) 2005-01-05 2006-07-13 Eli Lilly And Company Peptides agonistes de mc4r ou de mc3r lies a un polyethyleneglycol
EP1919947B1 (fr) 2005-08-26 2013-02-27 AbbVie Inc. Analogues alpha-msh therapeutiquement actifs

Also Published As

Publication number Publication date
PT2286825T (pt) 2017-01-02
PL2548568T3 (pl) 2018-06-29
IL188545A (en) 2011-08-31
EP2548568A3 (fr) 2013-07-17
EP1915167A4 (fr) 2010-04-07
JP2010090130A (ja) 2010-04-22
ES2663916T3 (es) 2018-04-17
CN101257916A (zh) 2008-09-03
PT3354273T (pt) 2021-06-28
AU2006269261A1 (en) 2007-01-18
EP2286825A3 (fr) 2011-07-27
EP2286825A2 (fr) 2011-02-23
US20180305406A1 (en) 2018-10-25
JP2015232003A (ja) 2015-12-24
RU2380372C2 (ru) 2010-01-27
CA2793119C (fr) 2019-07-23
PL2236151T3 (pl) 2012-10-31
HK1258965A1 (zh) 2019-11-22
WO2007008704A2 (fr) 2007-01-18
CA3044795A1 (fr) 2007-01-18
DK2286825T3 (en) 2017-01-09
KR101232201B1 (ko) 2013-02-12
US8039435B2 (en) 2011-10-18
RU2008104803A (ru) 2009-08-20
US20170240595A1 (en) 2017-08-24
CN103755786B (zh) 2016-05-11
RU2009131092A (ru) 2011-02-20
HK1149190A1 (en) 2011-09-30
JP5889513B2 (ja) 2016-03-22
EP2548568B1 (fr) 2018-01-10
CN101676298A (zh) 2010-03-24
CN105837661A (zh) 2016-08-10
CA2614615C (fr) 2012-10-16
IL201732A (en) 2016-07-31
HUE037147T2 (hu) 2018-08-28
EP2236151B1 (fr) 2012-05-23
EP3354273A1 (fr) 2018-08-01
EP2286825B1 (fr) 2016-09-28
US20160368962A1 (en) 2016-12-22
US20200095281A1 (en) 2020-03-26
NL301150I1 (fr) 2021-12-08
EP3925614A2 (fr) 2021-12-22
SG163585A1 (en) 2010-08-30
KR20100016120A (ko) 2010-02-12
ES2386862T3 (es) 2012-09-03
JP2013253090A (ja) 2013-12-19
DK2548568T3 (en) 2018-03-12
CA2793119A1 (fr) 2007-01-18
CA2614615A1 (fr) 2007-01-18
IL246392A (en) 2017-07-31
EP1915167A2 (fr) 2008-04-30
CN101257916B (zh) 2013-04-03
PT2236151E (pt) 2012-07-02
US20100279922A1 (en) 2010-11-04
DK3354273T3 (da) 2021-06-28
KR100997177B1 (ko) 2010-11-29
US20180105557A1 (en) 2018-04-19
IL188545A0 (en) 2008-04-13
PL3354273T3 (pl) 2021-10-11
DK2236151T3 (da) 2012-07-09
AU2006269261B2 (en) 2009-12-17
HUE031731T2 (en) 2017-07-28
HUS2100054I1 (hu) 2021-12-28
PL2286825T3 (pl) 2017-06-30
US9458195B2 (en) 2016-10-04
IL201732A0 (en) 2010-06-16
JP4734411B2 (ja) 2011-07-27
JP2009500427A (ja) 2009-01-08
NZ580806A (en) 2012-07-27
AU2009230799B2 (en) 2012-02-09
US20220127305A1 (en) 2022-04-28
EP3925614A3 (fr) 2022-03-23
RU2439079C2 (ru) 2012-01-10
EP2548568A2 (fr) 2013-01-23
HUE055154T2 (hu) 2021-11-29
EP2236151A1 (fr) 2010-10-06
SI3354273T1 (sl) 2021-10-29
KR20080049711A (ko) 2008-06-04
ES2604328T3 (es) 2017-03-06
WO2007008704A3 (fr) 2007-10-11
CA3228910A1 (fr) 2007-01-18
NZ565217A (en) 2010-03-26
FR21C1060I1 (fr) 2022-01-21
US9850280B2 (en) 2017-12-26
ES2877349T3 (es) 2021-11-16
NL301150I2 (nl) 2022-11-24
JP5965520B2 (ja) 2016-08-03
PT2548568T (pt) 2018-03-21
AU2009230799A1 (en) 2009-11-19
EP3354273B1 (fr) 2021-03-24
CN103755786A (zh) 2014-04-30
US20110183886A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
FR21C1060I2 (fr) Ligands des recepteurs de la melanocortine
DE602006003244D1 (de) Kopfstütze
DK1928882T3 (da) (s)-n-methylnaltrexon
DK1907574T3 (da) Oligonukleotider
DE112005003670A5 (de) Eventanordnung
NO20051629D0 (no) Festebrakett.
DE502006004816D1 (de) Verstellbeschlag
ITRM20050271A1 (it) Stuoia.
DE112006001399A5 (de) Baueinheit
DE502006002564D1 (de) Ndungen
FI7102U1 (fi) Istuin
FI20055601A (fi) Kannatin
UA11842S (uk) Кронштейн
NO20055812L (no) Installasjonsenhet
ITLU20050018A1 (it) Copertura per gronde
SE0502247L (sv) Referenslinje
UA12900S (uk) Емблема «трудовий союз»
FR2884491B1 (fr) Gouvernail de secours.
DE502006007306D1 (de) Halterungsanordnung
ES1061306Y (es) Mosquitera mejorada
FI6705U1 (fi) Suojus
DE502006001048D1 (de) Kombileiste
UA12206S (uk) Кришка
ITBS20050117A1 (it) Rivestimento per pellettati
UA13036S (uk) Барна стійка